Strides receives USFDA approval for Potassium Chloride for Oral Solution equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Strides gets USFDA nod for potassium chloride for oral solution
March 15, 2021
× Strides Pharma Science Limited (Strides) has announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food & Drug Administration (USFDA).
The product is bio-equivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride for Oral Solution USP, 20 mEq, of Pharma Research Software Solution, LLC.
Potassium chloride oral solution is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.
The product will be manufactured at the company s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.Strides Pharma Science (Strides) on Monday (15 March) announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for potassium chloride for oral solution USP, 20 mEq from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Potassium Chloride for Oral Solution USP, 20 mEq, of Pharma Research Software Solution.
According to IQVIA MAT January 2021 data, the US market for Potassium Chloride for Oral Solution USP, 20 mEq is approximately $56 million.
India, Maldives foreign minister level talks Friday
K’taka: Kalaburagi, Bidar districts record 666 covid cases
Six arrested for highway robbery of around Rs 1 80 lakh
Jain pays surprise visit to LNJP Hospital amid Covid-19 surge
TMC is on way out from Bengal: Anurag Thakur
40-yr-old Covid recovered man jumps to death in front of Express train in Thane
Kerala reports 8,778 new COVID cases, 2,642 recoveries: Health Minister
UP sees over 20k nCoV cases for first time; 68 deaths
UP prepares for 1st phase of panchayat polls in 18 districts on Thursday
Complete lockdown in Chhattisgarh s Bastar to contain coronavirus
Strides Pharma gains 3 per cent on FDA approval for Prednisone Tablets
February 12, 2021
The product will be manufactured at Bengaluru facility
The shares of Strides Pharma Science Limited (Strides) gained 3 per cent during the afternoon trade on Friday after the company announced that it had received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA).
At 1:13 pm, Strides Pharma was trading at ₹895.40 on the BSE, up ₹29.60 or 3.42 per cent.
It hit an intraday high of ₹902.25 and an intraday low of ₹868.45. It opened at ₹873.25 as against the previous close of ₹865.80.
On the NSE, it was trading at ₹895.00, up ₹28.75 or 3.32 per cent. It hit an intraday high of ₹902.00 and an intraday low of ₹866.30.